Guggenheim 3rd Annual Healthcare Innovation Conference - AXSOME THERAPEUTICS INC

Explicit Guidance:

• Cash Flow: Anticipates sustaining cash flow positivity in 2027, building on Q3 being the first cash flow positive quarter ($5–$6M profit excluding stock-based compensation).
• Gross-to-Net (GTN): Expects Q4 2025 GTN to potentially "tick up" due to high adjudication activity in the final two weeks; projects 2027 GTN to follow a similar quarterly pattern to 2026 unless the mix shifts toward the Medicare channel or coverage quality improves.
• Sales Growth: Qualitative guidance for 2026 and 2027 includes "continued robust growth" for Avelity, with accelerated growth specifically for the Alzheimer's Disease (AD) agitation indication; no specific revenue ranges provided.
• Synosy Peak Sales: Projects peak sales for current indications to reach $300–$500 million.

Business-Segment Outlook:

• Avelity (MDD & AD Agitation):
  • Growth Drivers: NBRx (New Beginnings Refill) velocity is a leading indicator; AD agitation NBRx grew 3.6x (1,000 to 3,600/month) post-approval by September 2025.
  • Refill Lag: Anticipates a "funnel" effect where Q3–Q4 NBRx growth translates into TRx (Refill) revenue growth over the next couple of quarters.
  • Sales Force: Expanded team from ~270 to ~650 reps (completed in Q2); expects ROI to materialize as reps reach 5–6 months tenure.
  • LTC Channel: Launching dedicated Long-Term Care focus; expects robust growth in this channel throughout the end of 2025 and 2026.
  • Primary Care: Aiming to increase penetration beyond the current ~25% share, leveraging strong payer access (89% MDD covered lives, 100% Medicare coverage).
• Synosy (EDS):
  • Current Indication: Growing in "low to mid single digits" quarterly with fixed OPEX (~$300k sales team, unchanged marketing spend).
  • Pipeline Expansion: Targeting Binge Eating Disorder (Q1 2026 top-line readout requiring two positive trials for NDA), MDD with EDS (enrollment completion expected next year), ADHD (pediatric studies needed post-positive adult trial), and Shift Work Disorder (one study required for NDA).
• AXS-12 (Rupoxetine):
  • Indication: Orphan indication for cataplexy and narcolepsy; PDUFA date set for May 1, 2027.
  • Commercial: Utilizing existing sleep team infrastructure with minimal incremental investment; expected to be "accretive to the P&L pretty quickly."

Market and Competitive Outlook:

• Competitive Landscape: Acknowledges increased placebo response rates in MDD and the emergence of orexin inhibitors; differentiates Avelity via distinct tolerability profiles and mechanistic differentiation for AXS-12.
• Payer Dynamics: 89% of MDD patients and 100% of Medicare patients have coverage; focus remains on improving coverage quality to "preferred, unrestricted, no PA" status to mitigate gross-to-net pressure.
• Demand Trends: "Very robust" clinician and patient feedback for Sembravo (acute migraine) despite navigating complex commercial dynamics; Avelity AD agitation launch tracking ahead of internal plans.

Macro / Industry Outlook:

• No specific commentary on interest rates, FX, or broad economic indicators; management focus remains on company-specific catalysts and execution.

Strategic Initiatives:

• Pipeline Acceleration: Targeting 2027 as a "big year" for milestones and catalysts, including PDUFA for AXS-12 (May 1) and potential NDA filings for Synosy indications (ADHD, Shift Work) pending positive trial data.
• Sales Force Optimization: Completed significant expansion in 2025; focus now on optimizing ROI and field team productivity.
• Long-Term Runway: Pipeline extends through early 2039 (pediatric indications for Avelity).
• Capital Allocation: Balance sheet strength ($314M cash) enables heavy upfront sales investments; strategy prioritizes top-line growth over margin expansion in the near term, though profitability is expected to improve with scale.

Risks and Headwinds to Outlook:

• Clinical Uncertainty: Potential failure in upcoming trials (Binge Eating Disorder requires two positive studies; Shift Work requires one; ADHD pediatric studies needed).
• Commercial Execution: Delay in TRx (refill) revenue catching up to NBRx (new prescription) growth; potential disruption from sales force expansion.
• Reimbursement: Quality of coverage (GTN) could decline if payer terms worsen or mix shifts away from high-quality coverage.
• Competitive Disruption: Increased placebo response rates in psychiatry trials and introduction of new competitors (orexin inhibitors, upcoming agents).
• Regulatory: FDA requirements for "standalone efficacy packages" for new indications (e.g., Binge Eating) may extend timelines.

Management Tone on the Future:

• Confidence: Described as "amazing," "frankly things have never been better," and "very pleased" with the commercial performance and pipeline trajectory.
• Strategic Hedges: Management explicitly notes that they "haven't shared that we're going to be sustained cashflow positive" but views the current positive Q3 as a "luxury" for decision-making; cautious on Q4 GTN guidance due to adjudication timing.
• Timing: Views 2027 as a potential inflection point for the company driven by multiple milestones.

Miscellaneous:

• Financial Milestone: Avelity revenue reached $208M (53% YoY growth, 15% sequential) in Q3 2025; company total revenue reached $260M, annualizing over $1B.
• Sembravo: Revenue reached $3.9M; growing from a volume perspective with strong clinical feedback.
• Synosy: Milestone revenue of ~$8.5M recognized in the quarter.